Article Text

other Versions

PDF
Extended report
Remission in systemic lupus erythematosus: durable remission is rare
  1. Theresa R Wilhelm1,2,
  2. Laurence S Magder3,
  3. Michelle Petri1
  1. 1Department of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA
  2. 2Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Glostrup, Denmark
  3. 3Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland, USA
  1. Correspondence to
    Theresa R Wilhelm, Videncenter for Reumatologi og Rygsygdomme, Rigshospitalet Glostrup, Nordre Ringvej 57, Glostrup 2600, Denmark; theresa.rita.wilhelm{at}regionh.dk

Abstract

Introduction Remission is the ultimate goal in systemic lupus erythematosus (SLE). In this study, we applied four definitions of remission agreed on by an international collaboration (Definitions of Remission in SLE, DORIS) to a large clinical cohort to estimate rates and predictors of remission.

Methods We applied the DORIS definitions of Clinical Remission, Complete Remission (requiring negative serologies), Clinical Remission on treatment (ROT) and Complete ROT. 2307 patients entered the cohort from 1987 to 2014 and were seen at least quarterly. Patients not in remission at cohort entry were followed prospectively. We used the Kaplan-Meier approach to estimate the time to remission and the time from remission to relapse. Cox regression was used to identify baseline factors associated with time to remission, adjusting for baseline disease activity and baseline treatment.

Results The median time to remission was 8.7, 11.0, 1.8 and 3.1 years for Clinical Remission, Complete Remission, Clinical ROT and Complete ROT, respectively. High baseline treatment was the major predictor of a longer time to remission, followed by high baseline activity. The median duration of remission for all definitions was 3 months. African-American ethnicity, baseline low C3 and baseline haematological activity were associated with longer time to remission for all definitions. Baseline anti-dsDNA and baseline low C4 were associated with longer time to Complete Remission and Complete ROT. Baseline low C4 was also negatively associated with Clinical Remission.

Conclusions Our results provide further insights into the frequency and duration of remission in SLE and call attention to the major role of baseline activity and baseline treatment in predicting remission.

  • Outcomes research
  • Systemic Lupus Erythematosus
  • Disease Activity

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Clinical and epidemiological research
    Ronald van Vollenhoven Alexandre Voskuyl George Bertsias Cynthia Aranow Martin Aringer Laurent Arnaud Anca Askanase Petra Balážová Eloisa Bonfa Hendrika Bootsma Dimitrios Boumpas Ian Bruce Ricard Cervera Ann Clarke Cindy Coney Nathalie Costedoat-Chalumeau László Czirják Ronald Derksen Andrea Doria Thomas Dörner Rebecca Fischer-Betz Ruth Fritsch-Stork Caroline Gordon Winfried Graninger Noémi Györi Frédéric Houssiau David Isenberg Soren Jacobsen David Jayne Annegret Kuhn Veronique Le Guern Kirsten Lerstrøm Roger Levy Francinne Machado-Ribeiro Xavier Mariette Jamil Missaykeh Eric Morand Marta Mosca Murat Inanc Sandra Navarra Irmgard Neumann Marzena Olesinska Michelle Petri Anisur Rahman Ole Petter Rekvig Jozef Rovensky Yehuda Shoenfeld Josef Smolen Angela Tincani Murray Urowitz Bernadette van Leeuw Carlos Vasconcelos Anne Voss Victoria P Werth Helena Zakharova Asad Zoma Matthias Schneider Michael Ward
  • Clinical and epidemiological research
    Margherita Zen Luca Iaccarino Mariele Gatto Silvano Bettio Francesca Saccon Anna Ghirardello Leonardo Punzi Andrea Doria